A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma.
FGFR2 fusion mutations
MT: Oligonucleotides: Therapies and Applications
combination therapy
intrahepatic cholangiocarcinoma
nucleic acid drugs
targeted therapy
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
12 Dec 2023
12 Dec 2023
Historique:
received:
25
05
2023
accepted:
29
09
2023
medline:
23
10
2023
pubmed:
23
10
2023
entrez:
23
10
2023
Statut:
epublish
Résumé
Pemigatinib, a pan-FGFR inhibitor, is approved to treat intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusion mutations. Improving its targeting of FGFR2 fusions remains an unmet clinical need due to its pan selectivity and resistance. Here, we report a cholesterol-conjugated DNA/RNA heteroduplex oligonucleotide targeting the chimeric site in
Identifiants
pubmed: 37869260
doi: 10.1016/j.omtn.2023.102047
pii: S2162-2531(23)00265-2
pmc: PMC10589379
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102047Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Int J Mol Sci. 2021 Dec 12;22(24):
pubmed: 34948156
J Control Release. 2020 Jul 10;323:240-252
pubmed: 32272123
Nat Biotechnol. 2021 Dec;39(12):1529-1536
pubmed: 34385691
Nat Chem. 2022 Mar;14(3):274-283
pubmed: 35115657
J Hematol Oncol. 2021 Feb 10;14(1):23
pubmed: 33568192
Front Oncol. 2022 Apr 04;12:860453
pubmed: 35444941
Methods Mol Biol. 2020;2176:113-119
pubmed: 32865786
Nat Rev Neurol. 2018 Jan;14(1):9-21
pubmed: 29192260
Hepatology. 2019 Jan;69(1):420-430
pubmed: 30070383
Mol Cancer Ther. 2017 Apr;16(4):614-624
pubmed: 28255027
Drug Resist Updat. 2001 Feb;4(1):9-15
pubmed: 11512155
Blood. 2010 Feb 18;115(7):1351-3
pubmed: 20007809
Hepatology. 2014 Apr;59(4):1427-34
pubmed: 24122810
Nat Commun. 2020 Apr 9;11(1):1755
pubmed: 32273511
Nat Commun. 2022 Mar 28;13(1):1642
pubmed: 35347134
J Hepatol. 2021 Oct;75(4):888-899
pubmed: 34052254
Cancer Sci. 2018 Nov;109(11):3503-3518
pubmed: 30191630
J Cell Mol Med. 2021 Jan;25(2):618-628
pubmed: 33277810
Curr Opin Gastroenterol. 2015 May;31(3):264-8
pubmed: 25763789
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Oncogene. 2018 Jun;37(24):3229-3242
pubmed: 29545603
Front Oncol. 2020 Jan 09;9:1480
pubmed: 31998641
Signal Transduct Target Ther. 2020 Sep 2;5(1):181
pubmed: 32879300
Expert Rev Anticancer Ther. 2022 Dec;22(12):1265-1274
pubmed: 36408971
PLoS Genet. 2014 Feb 13;10(2):e1004135
pubmed: 24550739
Nat Nanotechnol. 2021 Jun;16(6):630-643
pubmed: 34059811
Nat Commun. 2020 Nov 3;11(1):5559
pubmed: 33144569
Nucleic Acid Ther. 2018 Jun;28(3):128-136
pubmed: 29746209
Nat Rev Drug Discov. 2021 Jun;20(6):427-453
pubmed: 33762737
PLoS One. 2013;8(1):e52320
pubmed: 23382816
Ann Oncol. 2022 Dec;33(12):1269-1283
pubmed: 36089135
RNA Dis. 2016;3(4):
pubmed: 28374018
Cancer Metastasis Rev. 2020 Sep;39(3):603-623
pubmed: 32447477
Cancer Cell. 2022 Jan 10;40(1):70-87.e15
pubmed: 34971568
Mol Ther Nucleic Acids. 2020 Dec 03;23:1360-1370
pubmed: 33738132
Drug Resist Updat. 2022 Dec;65:100884
pubmed: 36252360
Oncologist. 2014 Mar;19(3):235-42
pubmed: 24563076
Hepatology. 2021 Sep;74(3):1357-1370
pubmed: 33709535
J Hepatol. 2020 Feb;72(2):353-363
pubmed: 31954497
J Clin Invest. 2021 Feb 1;131(3):
pubmed: 33301423
Biol Open. 2018 Dec 14;7(12):
pubmed: 30464009
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
Cell Death Dis. 2021 Mar 11;12(3):256
pubmed: 33692336
Gastroenterology. 2011 Jul;141(1):378-88, 388.e1-4
pubmed: 21440549
Mol Ther. 2021 Feb 3;29(2):838-847
pubmed: 33290725
Mol Cell Biol. 1989 Jun;9(6):2350-9
pubmed: 2569668
Gut. 2023 Apr;72(4):736-748
pubmed: 35584893
Ann Hepatol. 2022 Sep-Oct;27(5):100737
pubmed: 35809836
Cancer Discov. 2021 Feb;11(2):326-339
pubmed: 33218975
Cancer Med. 2019 Nov;8(16):6933-6944
pubmed: 31566899
J Exp Clin Cancer Res. 2021 Nov 3;40(1):345
pubmed: 34732230
Biology (Basel). 2014 May 30;3(2):345-67
pubmed: 24887773
Oncogene. 2023 May;42(18):1492-1507
pubmed: 36928362
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Drug Resist Updat. 2005 Jun;8(3):119-29
pubmed: 15869901
Cancer Discov. 2022 May 2;12(5):1378-1395
pubmed: 35420673
Drug Resist Updat. 2012 Feb-Apr;15(1-2):70-80
pubmed: 22325423
Clin Cancer Res. 2016 Jan 15;22(2):291-300
pubmed: 26405193
J Control Release. 2019 Nov 28;314:141-161
pubmed: 31644939
Clin Cancer Res. 2018 Sep 1;24(17):4154-4161
pubmed: 29848569
Recent Pat Anticancer Drug Discov. 2012 Jan;7(1):4-13
pubmed: 21854356
HPB (Oxford). 2017 Oct;19(10):901-909
pubmed: 28728891
Signal Transduct Target Ther. 2020 Jun 19;5(1):101
pubmed: 32561705
Biochim Biophys Acta Mol Basis Dis. 2019 May 1;1865(5):993-1002
pubmed: 31007176
Am J Pathol. 2014 Apr;184(4):912-923
pubmed: 24480331
Wiley Interdiscip Rev RNA. 2020 Sep;11(5):e1594
pubmed: 32233021